InflaRx NV
NASDAQ:IFRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (182.4), the stock would be worth $-179.95 (11 347% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.6 | $1.6 |
0%
|
| Industry Average | 182.4 | $-179.95 |
-11 347%
|
| Country Average | 15.5 | $-15.34 |
-1 059%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
|
InflaRx NV
NASDAQ:IFRX
|
115.7m USD | -1.6 | -2.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
354.5B USD | 19.6 | 84.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 14 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 15 | 19.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 22 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 14.8 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 41.9 | 38 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 13.1 | 30.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 10.6 |
| Median | 15.5 |
| 70th Percentile | 23.1 |
| Max | 672.9 |
Other Multiples
InflaRx NV
Glance View
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
